A global database of COVID-19 vaccinations 1 2

- Edouard Mathieu¹, Hannah Ritchie^{1,2*}, Esteban Ortiz-Ospina^{1,2}, Max Roser^{1,2}, Joe Hasell^{1,2,3}, 3 Cameron Appel¹, Charlie Giattino^{1,2} 4
- 5
- 6 ¹ Our World in Data
- 7 ² Oxford Martin Programme on Global Development, University of Oxford, Oxford, United
- 8 Kingdom
- 9 ³ Department of Social Policy and Intervention, University of Oxford, Oxford, United Kingdom
- 10

* Corresponding author 11

12

Abstract 13

- 14 An effective rollout of vaccinations against COVID-19 offers the most promising prospect of
- 15 bringing the pandemic to an end. We present the Our World in Data COVID-19 vaccination
- 16 dataset, a global public dataset that tracks the scale and rate of the vaccine rollout across
- 17 the world. This dataset is updated regularly, and includes data on the total number of
- 18 vaccinations administered; first and second doses administered; daily vaccination rates; and
- 19 population-adjusted coverage for all countries for which data is available (138 countries as of
- 20 17 March 2021). It will be maintained as the global vaccination campaign continues to
- 21 progress. This resource aids policymakers and researchers in understanding the rate of
- 22 current and potential vaccine rollout; the interactions with non-vaccination policy responses;
- 23 the potential impact of vaccinations on pandemic outcomes such as transmission, morbidity,
- 24 and mortality; and global inequalities in vaccine access.
- 25

Main 26

27 As of 17 March 2021 there have been 2.7 million confirmed deaths and 121 million 28 confirmed cases of SARS-CoV-2 — the virus that causes COVID-19.¹ Since the beginning of 29 the pandemic and up until today, virus transmission and mortality has been reduced through 30 a range of measures: precautionary actions from individuals including social distancing, 31 wearing facemasks, hand hygiene, and restricting interpersonal contact to outdoor settings; 32 widespread testing to identify individuals infected with the virus; and non-pharmaceutical 33 policy responses from governments - including school and workplace closures; bans on public gatherings; travel restrictions; and stay-at-home orders.^{2,3} Now, with the successful 34 35 development, evaluation and production of multiple vaccines, governments are turning 36 towards vaccination as an essential solution to the pandemic. 37

To understand the scale and rate of the vaccine rollout, we need timely, comparable data 38 39 across countries. The Our World in Data COVID-19 vaccination dataset provides a public 40 aggregated global dataset on administered vaccinations. It covers the full period from 13 41 December 2020 – the date of the first publication of vaccination data – and is being updated 42 regularly ever since. The COVID-19 vaccination dataset is continuously expanding as more 43 countries begin releasing official data on their new national vaccination campaigns. As of 17 44 March 2021, the dataset covers 138 countries. Our intention is to maintain this database for 45 the foreseeable future and include additional countries as the vaccination campaign starts in 46 a growing number of countries.

47

48 This dataset tracks the total number of COVID-19 vaccinations administered by country; 49 broken down by first and second doses (where national data is made available); and derived 50 daily vaccination rates and population-adjusted figures. The combination of these metrics 51 allows users to understand the scale and rate of vaccine rollouts relative to population: 52 compare rollout rates between countries; and assess differences in prioritization for 53 countries with one- and two-dose schedules. This data is compiled from official sources, 54 including health ministries, government reports and official social media accounts. 55 56 Our COVID-19 vaccination dataset is already used widely by journalists, policymakers,

researchers and the public. The World Health Organization (WHO) relies on this dataset for 57

its official COVID-19 dashboard.⁴ Our dataset is also used by policymakers to benchmark 58

- 59 the performance of national vaccination programs across countries. The WHO have also
- 60 relied on this dataset to understand the inequities in global vaccine access, using this

61 evidence to support calls for greater financial support for COVAX, a global initiative

62 supported by the WHO that is aimed at equitable access to COVID-19 vaccines

63

Our dataset has been used by all leading media outlets, including the New York Times, the 64 BBC, the Financial Times and The Economist.^{5–8} Global media plays an important role in 65 informing the public during this global pandemic, and it is essential that leading media 66 67 outlets have timely, transparent and reliable data to present to their audiences. The 68 demonstration of rapid vaccine rollouts across the world, and its potential impacts on 69 transmission and mortality has the potential to shape public attitudes towards vaccinations, 70 reduce vaccine hesitancy, and ultimately lead to an improved response to the pandemic. An 71 effective vaccination response relies on high uptake rates.⁹ As such, our dataset plays a key 72 role in building the public trust that is essential to an effective global response to the COVID-73 19 pandemic. 74

75 Our dataset has been widely-used by the scientific community across multiple disciplines. It 76 has been used to highlight global inequalities in vaccine access, with strong calls to action 77 for the acceleration of financial and policy response efforts to close the existing gaps.¹⁰ It 78 has been used by researchers to identify countries with particularly effective vaccine rollouts, 79 thereby enabling an analysis of how this was achieved.¹¹ These analyses emphasize a 80 range of drivers that explain the large differences across countries that we document: 81 differences in the funding of the development and production of the vaccines; differences in the scheduling and management of vaccinations; differences in public trust and uptake 82 rates; and differentiated responsibilities between national, regional and local level actors.¹² 83 84 Health policy researchers have used this dataset to assess differences in vaccine prioritization strategies — for example, which groups should be offered the vaccine first.¹³ 85 Other research groups have combined it with vaccine development data to provide a 86 complete overview of the global vaccine landscape.¹⁴ It has been used by researchers 87 looking at the role of vaccine hesitancy, and how to design public messaging based on these 88 concerns.15 89

90

91 As vaccination campaigns continue to scale, evidence for their effectiveness in reducing 92 transmission, severe disease and death will become increasingly important. Our dataset 93 provides an essential input for epidemiologists who study these questions. Integrating it with 94 other epidemiological data can help researchers evaluate these outcomes.^{16,17} Evidence of 95 positive impacts of vaccination on transmission and mortality can also in turn help to 96 strengthen public trust.


- 97 The rest of this article is organized as follows: The Results section presents the key metrics
- 98 used to track vaccine rollout in this dataset, and the headline results so far. The Discussion
- 99 section outlines the significance and limitations of this work. The Methods section provides
- 100 detailed descriptions of the underlying methods and sources used to build this global
- 101 dataset.

Results 102

103 Global coverage of COVID-19 vaccination campaigns

- 104 The first published reports of COVID-19 vaccinations (outside clinical trials) occurred on 13
- 105 December 2020 in the United Kingdom. Our live dataset presents the time-series of
- vaccinations across the world since then. 106
- 107
- 108 To date, 138 countries reported vaccinations, and are included in this dataset. As of 17
- 109 March 2021, there have been 400 million doses administered globally. 3% of the world
- 110 population have received at least one dose of an approved vaccine. This highlights
- 111 important inequalities in global vaccine access (Figure 1). At the time of writing most high-
- 112 and middle-income countries have begun vaccination rollouts, but many low-income
- countries have not (Figure 2). Only 11 countries in Sub-Saharan Africa had started 113
- 114 community vaccination.
- 115








CC BY

- 116 117 Figure 1: Cumulative number of COVID-19 doses administered by country. This represents the
- 118 current coverage of the global vaccination rollout.

119



Source: Official data collated by Our World in Data - Last updated 16 March, 09:22 (London time); World Bank OurWorldInData.org/covid-vaccinations • CC BY

120 121 Figure 2: Cumulative number of COVID-19 doses administered per 100 people, measured against 122 gross domestic product (GDP) per capita. GDP per capita is PPP-adjusted, and measured in 123 international-dollars.

124


Large differences in vaccination rates between countries 125

126 The data reveals large differences in the scale of the vaccine rollout across countries. As of

127 17 March 2021, we see the cumulative number of doses administered per 100 people range

- 128 from 110 per 100 in the case of Israel, to 0.01 doses per 100 in countries that have just
- 129 begun their vaccination campaigns, such as Nigeria, Iran and Vietnam (Figure 3).¹
- 130
- These differences in vaccination coverage are dependent on several factors. First, the date 131
- when countries started national vaccination campaigns: the United Kingdom, for example, 132
- began community vaccination on 8 December 2020 while other countries have not yet 133
- 134 begun their vaccine rollouts.
- 135

¹ As discussed below, the number of doses can exceed the number of people due to multiple dose vaccination programs.



¹³⁶ 137

Source: Official data collated by Our World in Data


CC BY



139 140

141 Second, the rate of vaccinations over time. We see large differences in these rates between countries (Figure 4a, b). Israel has received significant attention for the rate of its 142 campaign.¹¹ As well as being one of the first countries to begin vaccinations, it also 143 144 maintained a consistently high rate of vaccinations over time. This is reflected in its steep 145 linear time-series trend of cumulative doses (Figure 4a) and consistently high rate of daily 146 doses (Figure 4b). Since the end of December 2020 Israel has averaged a rate of 147 approximately one dose per 100 people per day — more than twice the rate of most 148 countries. Rosen et al. (2021) looked at the contributors to Israel's success and identified 149 factors such as the organisational and logistical capacity of its community-based healthcare 150 providers; a clear prioritisation framework; and effective outreach efforts to the public as 151 important.¹¹ Lee al. (2021) also looked at the factors in Israel's success, and emphasized the high level of public trust in particular.¹² 152 153

- 154 Most countries which have achieved the fastest vaccine rollouts to date — Israel, United
- Arab Emirates, United Kingdom, United States, Bahrain, and Chile are high-income 155
- countries. We see from Figure 2 that income matters. But the significant variation at different 156
- 157 income levels shows that it's not the only factor. This can be the basis for research into
- 158 effective strategies at different income levels.



159

- 160 Figure 4: Vaccine doses administered per 100 people: (a) shown as the cumulative total per 100 161 people; and (b) daily doses administered per 100 people (7-day smoothed) for select countries. 162
- 163

Different approaches and prioritization strategies between countries 164

165 The Our World in Data COVID-19 vaccination dataset allows for comparison of cumulative doses administered, and for a subset of countries, disaggregated data on the number of first 166 167 and second doses is available. This allows for a comparison of prioritization strategies – a

- 168 central policy and research question.
- 169

170 Our data highlights large differences in approaches taken by different countries. Some

- countries the United Kingdom being the most prominent example have taken a 'first 171
- 172 dose first' approach, delaying the delivery of a second vaccine dose to achieve wider single-
- 173 dose coverage within the total population. This is reflected in the data which shows the
- share of the total people that have received at least one dose of a COVID-19 vaccine 174
- 175 (Figure 5a) and the share that have been fully vaccinated (Figure 5b). As of 17 March
- 176 2021, 37.2% of the total population had received at least one dose, but only 2.6% had
- 177 received both doses. Other countries have put greater emphasis on giving two doses to a
- 178 smaller share of the population. In these countries a large share of those who received the
- 179 first dose have already received the second dose: In Israel, 59.5% had received at least one
- 180 dose, and 50.9% had been fully vaccinated. In the United States, 22% had received one
- 181 dose and 12% had been fully vaccinated.

182

Differences in prioritization have received particular attention in Europe. The 'first dose first' 183

- 184 approach favoured by the United Kingdom has been frequently contrasted with the approach
- of many countries in the European Union.^{18–20} This is reflected in our dataset: Germany, for 185
- example, has administered a first dose to a much smaller share of the population (8.1%) but 186
- 187 has fully vaccinated a higher share than the UK (3.6%). While the share of the population
- 188 that received a first dose in Germany was much lower than in the UK, the share who
- 189 received a second dose is actually higher.


	who received at least one do ation that received at least one vaccine d ses.				Share of the population that countries which report the break	t have received all dos	es prescribed by th	e vaccination proto		
Israel				59.5%	Israel					50.9%
United Kingdom		37	.2% (Mar 16, 2021)		United Arab Emirates		22.1% (F	eb 23, 2021)		
United Arab Emirates		35.2%	6 (Feb 23, 2021)		Chile	13.1%				
Chile		27.6%			United States	12%				
United States	22%				Serbia	11.9%				
Bahrain	22%				Turkey 4	.9%				
Serbia	18.6%				Denmark 4.	8% (Mar 16, 2021)				
Denmark	10.3% (Mar 16, 2021)				Poland 4.3	1% (Mar 16, 2021)				
Turkey	9.5%				Slovenia 4.1	% (Mar 16, 2021)				
Spain	8.7%				Spain 3.95	%				
Slovakia	8.3% (Mar 16, 2021)					% (Mar 16, 2021)				
Norway	8.3% (Mar 16, 2021)					% (Mar 16, 2021)				
Italy	8.2%				Italy 3.79					
Germany	8.2% (Mar 16, 2021)					6 (Mar 16, 2021)				
Poland	7.9% (Mar 16, 2021)				Portugal 3.4%					
France	7.8% (Mar 15, 2021)					(Mar 15, 2021)				
Brazil	4.5%					Mar 16, 2021)				
Russia	3.7%				Russia 1.7%					
Bangladesh	2.8% (Mar 16, 2021)				Brazil 1.5%					
Indonesia	1.7%				Indonesia 0.7%					
0%	10% 20%	30% 4	10% 50%		0%	10%	20%	30%	40%	50%
Source: Official data collate	d by Our World in Data - Last updated 18 Mar	rch, 08:40 (London time)	OurWorldi	InData.org/coronavirus + CC BY	Source: Official data collated by Our	World in Data – Last upda	ted 18 March, 08:40	(London time)	Our	WorldInData.org/coronavirus • CC BY

190

- 191 Figure 5: Share of the total population that have: (a) received at least one dose of the COVID-19 192 vaccine; and (b) been fully vaccinated against COVID-19, for select countries.
- 193

Discussion 194

- The rapid development, testing and manufacturing of multiple effective vaccines against 195
- SARS-CoV-2 was a ground-breaking achievement in 2020. Never before in history has a 196
- 197 vaccination campaign started so very soon after a new pathogen was identified. In many
- 198 cases it took many years or decades until a vaccine was developed (Figure 6). In the case of
- COVID-19 scientists have developed several, highly efficacious vaccines within the same 199
- year. The guestion now is whether the global rollout of the vaccine can match the speed with 200
- 201 which the vaccine was developed: whether they can be administered quickly and equitably
- 202 across the world.
- 203





206 Figure 6: Timeline of innovation in the development of vaccines. Each bar begins in the year in 207 which the pathogenic agent was first linked to the disease and the bar ends in the year in which a 208 vaccination against that pathogen was licensed in the US. 209

210

211 To do this, governments and public health officials need to understand the most effective 212 approaches to mass vaccination rollouts and prioritize the administration in a way that 213 minimizes morbidity and mortality from the disease. The dataset that we present here 214 provides an essential resource to support this. It allows analysts to track vaccinations over 215 time in a specific country, and also to compare vaccination rates and prioritization strategies 216 across countries. Combined with epidemiological data, it is a vital input for researchers to understand how vaccination affects the transmission and health outcomes of COVID-19. 217 218 219 Communicating such research on the efficacy of vaccines is in turn essential for building public trust and reducing vaccine hesitancy.^{21,22} Kreps et al. (2021) found that perceived 220

- 221 vaccine efficacy was the strongest predictor of COVID-19 vaccine uptake in the United
- 222 States.²³ Sherman et al. (2021) studied people's willingness to be vaccinated against
- COVID-19 and their attitude towards vaccines.²⁴ The researchers documented that the 223
- 224 effectiveness of vaccines in reducing disease is a particularly important argument.
- 225

226 It is important to highlight what we do not try to achieve with this dataset collection. We only

227 collect data on doses administered — we do not include data on the number of doses

- 228 manufactured, ordered or delivered. In the collection of data on administered doses we also
- do not audit official reports beyond technical validation (see Methods section). And we also
- 230 do not attempt to assess vaccine effectiveness or the impacts of vaccinations on pandemic
- 231 outcomes. This is beyond the scope of this resource.
- 232
- 233 If we want to understand anything about vaccines effectiveness, policy responses,
- 234 perceptions then we need to know how many vaccines have been administered. Our
- dataset fills this gap.

236 Methods

- 237 In this section we first provide a description of the metrics made available in this dataset,
- 238 followed by information on how this data was collected. Finally, we describe how it is
- 239 published as a complete, open-access dataset and how it can be explored via our online
- 240 web application.
- 241

242 Metrics included in this dataset

- The metrics included in this dataset are a combination of original metrics reported by officialsources, and derived metrics calculated by *Our World in Data*.
- 245

246 The nine metrics included in this dataset are the following.

- 247
- Total doses administered. This is a count of all doses given. Since several
 vaccines require multiple doses this count may be higher than the total number of
 people vaccinated.
- 251 2. Total doses administered per 100 people. This is 'Total doses administered' per
 252 100 people of the total population.
- 253 3. Daily vaccinations. If official sources provide daily updates of vaccinations
 254 administered, this is included.
- 4. Rolling average of daily vaccinations over 7 days. For countries that don't report
 data on a daily basis, we assume that the number of administered doses was the
 same on all days over any periods in which no daily data was reported. This
 produces a complete series of daily figures, which is then averaged over a rolling 7day window.
- 260 5. Daily doses administered per million people. This is the rolling average of daily
 261 vaccinations over 7 days, per million people within the total population.

262 6. Number of people that have received at least one vaccine dose. Depending on 263 the vaccine schedule (a one or two-dose vaccine), this may or may not match the 264 number of people fully vaccinated. If a person receives the first dose of a 2-dose 265 vaccine, this metric goes up by one. If they receive the second dose, the metric stays 266 the same. 267 7. Share of the total population that have received at least one vaccine dose. This 268 is the number of people that have received at least one vaccine dose per 100 people 269 in the total population. 270 8. Number of people that are fully vaccinated. This is the total number of people who 271 received all doses prescribed by the vaccination protocol. If a person receives the 272 first dose of a two-dose vaccine, this metric stays the same. If they receive the 273 second dose, the metric goes up by one. 274 9. Share of the total population that are fully vaccinated. This is the number of 275 people that have received all doses prescribed by the vaccination protocol per 100 276 people in the total population. 277 278 Not all metrics are available for all countries. The availability is dependent on the granularity 279 of reporting provided by the official sources. For example, not all countries provide a 280 breakdown of doses administered by first or second doses. In this case, only the total 281 number of administered doses can be provided for this country. 282 **Data collection methods** 283 284 Raw data on vaccination doses administered is collected through a combination of manual 285 and automated means. This collection process differs by country, but can be broadly defined 286 by three methods. 287 Firstly, for a number of countries, figures reported in official sources — including government 288 289 websites, health ministries, dedicated dashboards, and social media accounts of national 290 authorities — are recorded manually as they are released. 291 292 Secondly, where official sources release vaccination figures in a consistent, machine-293 readable format, or where structured data is published at a stable location, we have 294 automated the data collection via Python scripts that we execute every day. These 295 automated scripts are made available in our GitHub repository 296 (https://github.com/owid/covid-19-297 data/blob/master/scripts/scripts/vaccinations/automations/). These are regularly audited for

technical bugs to ensure data validity (see 'Technical Validation', below).

- 299
- 300 Third, in some instances where national data is not made available in machine-readable
- 301 format by official sources, but is aggregated by third-party sources we source data from
- 302 non-official publishers (e.g. <u>https://covid19tracker.ca/vaccinationtracker.html</u> for Canada).
- 303 These are also regularly audited for accuracy against the original official sources.
- 304

305 Calculating derived metrics

- 306 Derived metrics are calculated from the raw official counts in two ways.
- 307
- 308 1. Population-adjusted metrics. This normalizes total doses, first doses, and second doses
- 309 to their counts per 100 people within the total population. This allows users to compare the
- 310 pace and scope of the vaccination rollout across countries. Vaccinations administered per
- 311 100 people are calculated by dividing administered doses by total population figures,
- 312 sourced from the latest revision of the United Nations World Population Prospects.²⁵ The
- 313 exact population values used in these calculations are also provided in our GitHub repository
- 314 (https://github.com/owid/covid-19-data/blob/master/scripts/input/un/population_2020.csv).
- 315
- 2. Daily rolling averages. Not all countries report figures at a daily frequency. In order to
- 317 facilitate cross-country comparisons over time, we therefore derive a 'smoothed' daily
- 318 vaccination series calculated as the seven-day moving average. It is calculated as the right-
- 319 aligned rolling seven-day average of a complete series of daily changes. For countries for
- 320 which no complete series of daily changes is available from our source, we derive it by
- 321 linearly interpolating the cumulative totals. The exact code used to derive the 7-day moving
- 322 average is available online (see 'Code Availability', below).
- 323

324 Criteria for inclusion and coverage

- To be included in this dataset, countries must provide at least one data point on the number
- of vaccine doses administered via a trusted country-specific source such as a health
- 327 ministry, government report or official national account. Reports on the number of vaccine
- 328 doses ordered or distributed are not included; this dataset only includes doses administered.
- 329 Vaccinations administered in clinical trials are also not included.
- 330
- As of 17 March 2021, the vaccination dataset covers 138 countries. This coverage will
- 332 continue to expand as more countries begin vaccination campaigns.
- 333

Technical validation 334

- 335 The Our World in Data COVID-19 vaccination database represents a collation of publicly 336 available data published by official sources. The main quality concern for the database itself 337 is whether it represents an accurate record of the official data. We employ several strategies 338 to ensure that this is the case.
- 339

340 First, all automated collection of data, whether obtained from official channels or non-official 341 publishers, is subject to initial manual verification when it is added to our database for the 342 first time.

343

344 Second, we employ a range of data validation processes, both for our manual and

345 automated time series. We continually check for invalid figures such as negative or illogical

- 346 values, out-of-sequence dates, implausible changes in time-series data, invalid population-
- 347 adjusted values, and for each country we test for abrupt changes in vaccination rates.
- 348

349 Third, our vaccination data is viewed and used by millions of people every day — either

- 350 through direct usage or third-party usage (such as news reports, social media and other
- 351 sharing channels). This includes employees of health ministries, researchers, journalists,
- 352 and policymakers from across the world. We receive large amounts of feedback from this
- 353 user base. This provides a final 'crowd-sourced' verification method that has been shown to
- 354 be effective in highlighting any discrepancies to official data sources.
- 355

356 Data access and publication

357 Vaccination data is updated daily and is made available via two channels. Firstly, all data 358 and scripts used for data collection are published and updated in our public GitHub

359 repository (https://github.com/owid/covid-19-data/tree/master/public/data/vaccinations). This

- provides a transparent resource for users to download the data in CSV and JSON formats; 360
- 361 replicate the data collection and metric derivation process; and monitor any changes or
- 362 additions to this process.
- 363

364 To allow journalists, researchers, policymakers and the public to understand the evolution of 365 the global COVID-19 vaccination rollout, we make all of this data explorable at our online

- 366 web publication (ourworldindata.org/covid-vaccinations). There we provide interactive
- visualizations of all available vaccination metrics to allow users to track and compare the 367
- 368 vaccination campaigns around the world. These interactive visualizations are built with our

- 369 custom visualization tool the Our World in Data Grapher and are made available open-
- access. They are updated daily in sync with updates in our GitHub repository.

371 Data availability

- 372 A live version of the vaccination dataset and documentation are available in a public GitHub
- 373 repository at <u>https://github.com/owid/covid-19-data/tree/master/public/data/vaccinations</u>.
- 374 This data can be downloaded in CSV and JSON formats.

375 Code availability

- 376 Our scripts for data collection, processing, and transformation, are available for inspection in
- 377 the public GitHub repository that hosts our data (<u>https://github.com/owid/covid-19-</u>
- 378 <u>data/tree/master/scripts/scripts/vaccinations</u>).
- 379

380 References

- 1. Data as of 17 March 2021 from the online repository published by the Center for
- 382 Systems Science and Engineering (CSSE) at Johns Hopkins University: Dong, E., Du, H.,
- 383 & Gardner, L. (2020). An interactive web-based dashboard to track COVID-19 in real
 384 time. .
- 385 2. Hale, T. et al. Tracker). Nat. Hum. Behav. (2021). doi:10.1038/s41562-021-01079-8
- Hasell, J., Math, E., Beltek, D. & Macdonald, B. A cross-country database of COVID-19
 testing. *Nat. Sci. Data* 1–7 (2020). doi:10.1038/s41597-020-00688-8
- 388 4. https://covid19.who.int/info.
- 389 5. https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html.
- 390 6. https://www.bbc.co.uk/news/world-56237778.
- 391 7. https://ig.ft.com/coronavirus-vaccine-tracker/.
- 392 8. https://www.economist.com/graphic-detail/tracking-coronavirus-across-the-world.
- 393 9. Kim, J. H., Marks, F. & Clemens, J. D. Looking beyond COVID-19 vaccine phase 3 trials.
 394 *Nat. Med.* 27, 205–211 (2021).
- 395 10. Wilson, B. S. & Tucci, D. L. Priorities for the COVID-19 pandemic at the start of 2021:
- 396 statement of the Lancet COVID-19 Commission. *Lancet* 947–950 (2021).

- 397 doi:10.1016/S0140-6736(21)00388-3
- 11. Rosen, B., Waitzberg, R. & Israeli, A. Israel's rapid rollout of vaccinations for COVID-398
- 399 19. Isr. J. Health Policy Res. 6, 1–14 (2021).
- 400 12. Lee, H., T. & Chen, H., A. Last-Mile Logistics of Covid Vaccination — The Role of Health 401 Care Organizations. N. Engl. J. Med. 685–687 (2021).
- 402 13. Cylus, J., Panteli, D. & Ginneken, E. Van. Who should be vaccinated first ? Comparing 403 vaccine prioritization strategies in Israel and European countries using the Covid-19
- Health System Response Monitor. Isr. J. Health Policy Res. 1, 4–6 (2021). 404
- 405 14. Shrotri, M., Swinnen, T., Kampmann, B. & Parker, E. P. K. An interactive website
- 406 tracking COVID-19 vaccine development. *Lancet Glob. Heal.* 19–21 (2021).
- 407 doi:10.1016/S2214-109X(21)00043-7
- 408 15. Alkandari, D., Herbert, J. A., Alkhalaf, M. A., Yates, C. & Panagiotou, S. SARS-CoV-2 409 vaccines: fast track versus efficacy. The Lancet Microbe 2, e89–e90 (2021).
- 410 16. Dagan, N. et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination 411 Setting. N. Engl. J. Med. 1–12 (2021). doi:10.1056/NEJMoa2101765
- 412 Ramos, A. M., Vela-Perez, M., Ferrandez, M. R., Kubik, A. B. & Ivorra, B. Modeling the 17. 413 impact of SARS-CoV-2 variants and vaccines on the spread of COVID-19. (2021).
- doi:10.13140/RG.2.2.32580.24967/2 414
- 415 18. lacobucci, G. & Mahase, E. Covid-19 vaccination: What's the evidence for extending the dosing interval? BMJ 372, (2021). 416
- 417 19. Mahase, E. Covid-19 : Medical community split over vaccine interval policy as WHO recommends six weeks. BMJ (2021). doi:10.1136/bmj.n18 418
- 20. Baraniuk, C. Covid-19 : How the UK vaccine rollout delivered success, so far. BMJ 419 420 (2021). doi:10.1136/bmj.n421
- 421 21. Vanderslott, S., Dadonaite, B. & Roser, M. Vaccination. OurWorldinData.org Available 422 at: https://ourworldindata.org/vaccination.
- 423 22. Verger, P. & Dubé, E. Expert Review of Vaccines Restoring confidence in vaccines in the COVID-19 era. Expert Rev. Vaccines 19, 991–994 (2020). 424
- 23. Kreps, S. et al. Factors Associated With US Adults' Likelihood of Accepting COVID-19 425
- 426 Vaccination. JAMA Netw. Open 1–13 (2020).
- 427 doi:10.1001/jamanetworkopen.2020.25594
- 428 24. Sherman, S. M. et al. COVID-19 vaccination intention in the UK : results from the

- 429 COVID-19 vaccination acceptability study (CoVAccS), a nationally representative
- 430 cross- sectional survey. *Hum. Vaccin. Immunother.* 1–10 (2020).
- 431 doi:10.1080/21645515.2020.1846397
- 432 25. United Nations, Department of Economic and Social Affairs, P. D. World Population
- 433 Prospects: The 2019 Revision, DVD Edition. (2019).
- 434
- 435